Format
Items per page
Sort by

Send to:

Choose Destination

Results: 7

Cited In for PubMed (Select 11193580)

1.

Protein kinase C: an attractive target for cancer therapy.

Marengo B, De Ciucis C, Ricciarelli R, Pronzato MA, Marinari UM, Domenicotti C.

Cancers (Basel). 2011 Feb 1;3(1):531-67. doi: 10.3390/cancers3010531.

2.

PKC signaling in glioblastoma.

do Carmo A, Balça-Silva J, Matias D, Lopes MC.

Cancer Biol Ther. 2013 Apr;14(4):287-94. doi: 10.4161/cbt.23615. Epub 2013 Jan 28. Review.

3.

The active Zot domain (aa 288-293) increases ZO-1 and myosin 1C serine/threonine phosphorylation, alters interaction between ZO-1 and its binding partners, and induces tight junction disassembly through proteinase activated receptor 2 activation.

Goldblum SE, Rai U, Tripathi A, Thakar M, De Leo L, Di Toro N, Not T, Ramachandran R, Puche AC, Hollenberg MD, Fasano A.

FASEB J. 2011 Jan;25(1):144-58. doi: 10.1096/fj.10-158972. Epub 2010 Sep 17.

4.

Tight junctions: a barrier to the initiation and progression of breast cancer?

Brennan K, Offiah G, McSherry EA, Hopkins AM.

J Biomed Biotechnol. 2010;2010:460607. doi: 10.1155/2010/460607. Epub 2009 Nov 15. Review.

5.

Phosphorylation of claudin-4 by PKCepsilon regulates tight junction barrier function in ovarian cancer cells.

D'Souza T, Indig FE, Morin PJ.

Exp Cell Res. 2007 Sep 10;313(15):3364-75. Epub 2007 Jul 13.

6.

The transcription factors Slug and Snail act as repressors of Claudin-1 expression in epithelial cells.

Martínez-Estrada OM, Cullerés A, Soriano FX, Peinado H, Bolós V, Martínez FO, Reina M, Cano A, Fabre M, Vilaró S.

Biochem J. 2006 Mar 1;394(Pt 2):449-57.

7.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk